Levofloxacin Ecolevid, 500 mg 10 pcs

It has a protective effect on the normal intestinal microflora, thus it has increased gastrointestinal safety.

Along with the powerful broad spectrum antibacterial action, it has an immunomodulatory effect, which may be particularly important in the treatment of chronic or recurrent infectious aetiology diseases.

Indications

Infectious inflammatory diseases caused by microorganisms sensitive to the drug:

Active ingredient

Composition

One tablet contains:

Active ingredient:

levofloxacin hemihydrate (in terms of levofloxacin) 500 mg;

Auxiliary substances:

Lactulose,

lactose monohydrate,

povidone low molecular weight,

croscarmellose sodium,

sodium lauryl sulfate,

talc,

magnesium stearate,

microcrystalline cellulose;

Shell excipients:

Hypromellose, talc, titanium dioxide, macrogol-4000.

How to take, the dosage

Orally, before a meal or between meals, without chewing, drinking plenty of fluids.
Acute maxillary sinusitis: 500 mg 1 time per day for 10-14 days;
Community-acquired pneumonia: 500 mg once or twice daily for 7-14 days;
Exacerbation of chronic bronchitis: 250-500 mg once daily for 7-10 days;
Uncomplicated urinary tract infections- 250 mg once daily for 3 days;
Complicated urinary tract infections (including.including pyelonephritis): 250 mg 1 time per day (if the course of disease is severe the dose should be increased) for 7-10 days;
Chronic bacterial prostatitis – 500 mg 1 time per day, the course of treatment – 28 days;
Skin and soft tissue infections: 250-500 mg 1-2 times a day for 7-14 days;
Intraabdominal infection – 500 mg once a day, treatment course 7-14 days (in combination with antibacterial drugs acting on anaerobic microflora);
Complex therapy of drug-resistant forms of tuberculosis: 500 mg 1-2 times a day, treatment course – up to 3 months;
Duration of treatment depends on the type and severity of the disease.
After relief of acute inflammation symptoms and normalization of temperature it is recommended to continue treatment with levofloxacin for 48-72 hours.

Dosage of the drug in patients with impaired renal function (creatinine clearance less than 50 ml/min):

19-10 ml/min:
Initial dose of 250 mg/24 h: then 125 mg/48 h;
Initial dose of 500 mg/24 h: then 125 mg/24 h;
Initial dose 500 mg/12 h: then 125 mg/12 h;

10* ml/min:
Initial dose of 250 mg/24 h: then 125 mg/48 h;
Initial dose of 500 mg/24 h: then 125 mg/24 h;
Initial dose of 500 mg/12 h: then 125 mg/24 h;

*including. In hemodialysis and permanent ambulatory peritoneal dialysis

No additional doses are required after hemodialysis or permanent ambulatory peritoneal dialysis.
No dose adjustment is required in patients with hepatic dysfunction.

Interaction

There are reports of a marked decrease in seizure threshold with concomitant use of quinolones and substances that reduce cerebral seizure threshold. This also applies to the simultaneous use of quinolones and theophylline, as well as nonsteroidal anti-inflammatory drugs – propionic acid derivatives.

The action of the drug is impaired when concomitant use with sucralfate, antacids containing magnesium or aluminum, and iron salts. Levofloxacin should be taken at least 2 hours before taking these drugs.

When concomitant use of vitamin K antagonists, clotting system parameters should be monitored.
Renal clearance of levofloxacin is slightly delayed by cimetidine and probenecid. Levofloxacin slightly increases the half-life of cyclosporine.

The administration of glucocorticosteroids increases the risk of tendon rupture.

Special Instructions

When treating elderly patients it should be borne in mind that they often suffer from renal dysfunction.

While photosensitization against the background of treatment with levofloxacin is quite rare, patients should not be exposed to strong sunlight or artificial ultraviolet radiation.

In case of suspected pseudomembranous colitis levofloxacin should be immediately withdrawn and appropriate treatment should be started. In such cases, drugs that inhibit intestinal motility should not be used.

Patients with glucose-6-phosphate dehydrogenase deficiency (hereditary metabolic disorder) may respond to fluoroquinolones by destruction of red blood cells (hemolysis). In this regard, treatment with levofloxacin should be carried out with caution.
Side effects of levofloxacin such as dizziness or somnolence as well as visual disturbances (see section “Side effects”) may impair responsiveness and make it difficult to drive, operate machines and mechanisms.

Contraindications

Hypersensitivity to levofloxacin, other fluoroquinolones or drug components, epilepsy, tendon lesions in previous treatment with quinolones, pregnancy, lactation, childhood and adolescence (under 18 years).

Lactose intolerance or lactase deficiency and glucose-galactose malabsorption.

With caution in the elderly, with glucose-6-phosphate dehydrogenase deficiency.

Side effects

Digestive system disorders: nausea, vomiting, diarrhea (including blood), digestive disorders, decreased appetite, abdominal pain, pseudomembranous colitis; increased liver transaminase activity, hyperbilirubinemia, hepatitis, dysbacteriosis.

Cardiovascular system: decreased arterial pressure, vascular collapse, tachycardia, prolongation of QT interval, atrial fibrillation.

Nervous system disorders: headache, dizziness, weakness, drowsiness, insomnia, tremor, anxiety, paresthesias, fear, hallucinations, confusion, depression, motor disorders, seizures.

Sensory organs: disorders of vision, hearing, smell, taste and tactile sensitivity.

Musculoskeletal system: arthralgia, muscle weakness, myalgia, tendon rupture, tendinitis, rhabdomyolysis.

Urinary system disorders: hypercreatininemia, interstitial nephritis, acute renal failure.

Hematopoietic system disorders: eosinophilia, hemolytic anemia, leukopenia, neutropenia, agranulocytosis, thrombocytopenia, pancytopenia, hemorrhages.

Metabolic side: hypoglycemia (increased appetite, increased sweating, trembling).

Allergic reactions: itching and hyperemia of the skin, swelling of the skin and mucous membranes, urticaria, erythema malignant exudative (Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell syndrome), bronchospasm, choking, anaphylactic shock, allergic pneumonitis, vasculitis.

Other: asthenia, exacerbation of porphyria, photosensitization, persistent fever, development of superinfection.

Overdose

The symptoms of levofloxacin overdose are manifested at the level of the central nervous system (confusion, dizziness, impaired consciousness and seizures). In addition, gastrointestinal disorders (e.g., nausea, vomiting) and erosive lesions of the mucous membranes of the gastrointestinal tract may be noted.

Levofloxacin has been shown to prolong the QT interval in studies using ultra-high doses.

Levofloxacin is not excreted by hemodialysis or peritoneal dialysis. There is no specific antidote (antagonist).

The treatment is gastric lavage and symptomatic therapy.

Similarities